A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2005
This study will evaluate the efficacy, safety, tolerability, and pharmacokinetics of oral GK Activator (2), compared to placebo, in patients with type 2 diabetes mellitus. The anticipated time on study treatment is less than 3 months, and the target sample size is 100-500 individuals.
Epistemonikos ID: 819e020120062a9bdaae9d44fdf95b23e9f0d82f
First added on: May 04, 2024